Wu N Z, Da D, Rudoll T L, Needham D, Whorton A R, Dewhirst M W
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710.
Cancer Res. 1993 Aug 15;53(16):3765-70.
Stealth liposomes have recently emerged as a promising antitumor drug delivery system, yet no studies have been reported to examine their dynamic behavior at the microcirculatory level. In this investigation, we have used in vivo fluorescence videomicroscopy to study the decay in plasma concentration and the interstitial accumulation of Stealth and conventional liposomes in tumor and granulating tissue microcirculatory preparations. Fluorescently labeled Stealth or conventional liposomes were injected i.v. into rats bearing dorsal skinflap window chambers, some of which contained a vascularized mammary adenocarcinoma. After injection, fluorescent light intensities arising from liposomes within blood vessels and the interstitium were measured over time. These measurements were used to derive plasma pharmacokinetics and vascular permeability coefficients for each liposome species in both tumor and granulating normal tissues. Within the first 90 min after injection, Stealth liposome accumulation in the tumor interstitium was 3-4-fold that for conventional liposomes. The percentage of administered liposomes remaining in the circulation at the end of 90 min was 60.2% for Stealth and 20.4% for conventional liposomes. Tumor vascular permeability was 3.42 +/- 0.78 x 10(-7)cm/s for Stealth and 1.75 x 0.38 x 10(-7)cm/s for conventional liposomes. In normal granulating tissues permeability for the 2 constructs was equivalent at 0.8-0.9 x 10(-7)cm/s. In conclusion, preferential accumulation of Stealth liposomes in tumors was attributable to a combination of slower plasma clearance and higher vascular permeability relative to conventional liposomes. Our method of combining in vivo microscopy with a tumor microcirculatory model provides a unique approach to study quantitatively the delivery of liposomes to tumor tissues, since it can be used to study the process in real time at the microcirculatory level.
隐形脂质体最近已成为一种很有前景的抗肿瘤药物递送系统,但尚未有研究报道其在微循环水平的动态行为。在本研究中,我们利用体内荧光视频显微镜研究了隐形脂质体和常规脂质体在肿瘤和肉芽组织微循环制剂中的血浆浓度衰减及间质蓄积情况。将荧光标记的隐形或常规脂质体静脉注射到患有背部皮瓣窗口室的大鼠体内,其中一些含有血管化的乳腺腺癌。注射后,随时间测量血管内和间质中脂质体产生的荧光强度。这些测量结果用于推导每种脂质体在肿瘤和肉芽正常组织中的血浆药代动力学和血管通透性系数。注射后的前90分钟内,隐形脂质体在肿瘤间质中的蓄积量是常规脂质体的3至4倍。90分钟结束时,循环中剩余的给药脂质体百分比,隐形脂质体为60.2%,常规脂质体为20.4%。隐形脂质体的肿瘤血管通透性为3.42±0.78×10⁻⁷cm/s,常规脂质体为1.75×0.38×10⁻⁷cm/s。在正常肉芽组织中,两种制剂的通透性相当,为0.8 - 0.9×10⁻⁷cm/s。总之,相对于常规脂质体,隐形脂质体在肿瘤中的优先蓄积归因于血浆清除较慢和血管通透性较高的综合作用。我们将体内显微镜检查与肿瘤微循环模型相结合的方法提供了一种独特的途径来定量研究脂质体向肿瘤组织的递送,因为它可用于在微循环水平实时研究这一过程。